Researchers and physician-scientists often need practical advice for getting their work published. Here are insights into how to select an appropriate publication, manage co-author relationships and more from a panel of experts in both rheumatology and publishing.
This guidance from the ACR provides information about new remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) treatment management codes
A bill approved last year by the House Appropriations Committee contains dire cuts to funding for the National Institutes of Health. The ACR is urging the House to revise this language and the Senate not to allow these cuts to go through. Contact your legislators to convey the importance of robust investment in the nation’s medical research enterprise and how funding cuts harm patient care.
ACR members in private practice on The Community Practice Council can answer questions, share experiences and offer encouragement to those interested in private practice.
An error in UnitedHealthcare’s claims processing system resulted in underpayments on J code claims dated Oct. 8–Nov. 8, 2023. Practices are encouraged to review all J code payments from the final quarter of 2023.
New Committee on Rheumatologic Care (CORC) Chair Chris Phillips, MD, talks about his past work with the ACR, his experience as a private practice rheumatologist and his plans to lead CORC in addressing practitioner pain points and supporting the business side of rheumatology practice.
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
Last month, the ACR’s delegation to the AMA House of Delegates discussed and advanced resolutions to address specialty workforce shortages, payment reform and access to care.